List of Excipients in Branded Drug LIDOCAINE HCI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	LIDOCAINE HCI	lidocaine hci	51662-1364	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	LIDOCAINE HCI	lidocaine hci	51662-1364	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	LIDOCAINE HCI	lidocaine hci	51662-1364	SODIUM HYDROXIDE

Generic Drugs Containing LIDOCAINE HCI

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA Health First	lidocaine hci	51662-1230	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA Health First	lidocaine hci	51662-1230	SODIUM CHLORIDE
HF Acquisition Co LLC DBA Health First	lidocaine hci	51662-1230	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in LIDOCAINE HCI?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
9	HYDROCHLORIC ACID
4	METHYLPARABEN

Lidocaine HCl Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 27, 2026

Lidocaine hydrochloride is an off-patent local anesthetic with broad demand across injectable, topical, dental, ophthalmic, otic, and transdermal products. The active ingredient offers limited composition-of-matter protection, so commercial value is concentrated in formulation performance, delivery systems, preservative selection, device integration, manufacturing reliability, and regulatory execution.

The strongest opportunities are preservative-free multidose systems, low-irritation topical products, long-wear patches, fast-dissolving oral and dental dosage forms, and combination products that improve adherence or reduce administration burden. Biosimilar risk does not apply because lidocaine HCl is a chemically synthesized small molecule.

What is the commercial market for lidocaine hydrochloride?

Lidocaine HCl is used for local or regional anesthesia, topical analgesia, arrhythmia treatment in selected injectable products, and procedural pain control. Its commercial forms include:

Product category	Typical strength	Primary use	Commercial characteristics
Injectable solution	0.5%, 1%, 2%	Local infiltration, nerve block, epidural use	Hospital and ambulatory-procedure demand
Injectable antiarrhythmic	1% or 2%	Ventricular arrhythmias in specific settings	Sterile manufacturing and supply reliability are critical
Topical cream, gel, ointment	2% to 5%	Skin, mucosal, anorectal, dental pain	Retail, prescription, and professional channels
Oral viscous solution	2%	Mouth and throat anesthesia	Excipient tolerability and dosing safety are important
Topical solution or spray	4% to 10%	Mucosal or procedural anesthesia	Fast onset and metered delivery drive differentiation
Transdermal patch	Commonly 5% or 1.8%	Localized neuropathic pain	Adhesion, wear time, and skin tolerability create barriers
Dental cartridge	Commonly 2% with vasoconstrictor	Dental anesthesia	Container-closure and sterile fill-finish capabilities matter

Lidocaine HCl is generally supplied as a water-soluble salt. The free-base form is more suitable for certain lipidic or topical systems, while the hydrochloride salt is favored for aqueous injectable and mucosal products.

What excipients are used in lidocaine HCl formulations?

Excipients depend on the route, target tissue, required shelf life, and product architecture. The main formulation functions are solubilization, isotonicity, pH control, preservation, viscosity adjustment, adhesion, permeation control, and sensory masking.

Injectable lidocaine HCl

A conventional aqueous injection may contain:

• Water for injection
• Sodium chloride for isotonicity
• Hydrochloric acid or sodium hydroxide for pH adjustment
• Preservatives such as methylparaben in selected multidose products
• Sodium metabisulfite or related antioxidants in some products containing epinephrine
• Nitrogen overfill or controlled headspace in oxygen-sensitive presentations

Preservative-free presentations generally use single-dose vials, ampoules, prefilled syringes, or cartridges. The commercial tradeoff is clear: multidose products reduce handling cost, while preservative-free products expand use in neuraxial, ophthalmic, neonatal, and other settings where preservative exposure is restricted.

Injectable lidocaine HCl must control pH, particulate matter, sterility, endotoxin, extractables, leachables, and container compatibility. Glass vials, polymer syringes, dental cartridges, and plastic infusion containers can produce different stability and adsorption profiles.

Topical creams, gels, and ointments

Topical products may use:

• Water and humectants
• Propylene glycol, polyethylene glycol, or glycerin
• Carbomers, cellulose derivatives, poloxamers, or other rheology modifiers
• Fatty alcohols and emulsifiers in creams
• Mineral oil, petrolatum, or other occlusive components in ointments
• Preservatives such as parabens, phenoxyethanol, or organic acids
• Buffers and pH modifiers
• Chelating agents such as disodium edetate
• Fragrance, flavor, or cooling agents where acceptable

A key design issue is whether the product should maximize drug release from the vehicle or retain lidocaine within the formulation for prolonged local action. High levels of propylene glycol can improve solubilization and skin penetration but may increase irritation in sensitive users. Carbomer systems can provide high viscosity and residence time, but they may require neutralization and can interact with salts.

Oral viscous and mucosal products

Oral lidocaine HCl solutions commonly require:

• Purified water
• Viscosity enhancers
• Sweeteners such as saccharin sodium
• Flavors
• Humectants or cosolvents
• Preservatives
• pH adjusters

The principal development risks are accidental swallowing, systemic exposure, dosing errors, and local irritation. Viscosity can improve mucosal residence time but also raises the risk of prolonged numbness and impaired swallowing. Child-resistant packaging, calibrated dosing devices, and clear maximum-dose instructions are commercial and regulatory differentiators.

Transdermal patches

Patch products require an excipient system that is also a drug-delivery device. Components can include:

• Pressure-sensitive adhesive
• Polymer matrix or drug-in-adhesive layer
• Backing film
• Release liner
• Permeation modifiers
• Stabilizers
• Skin-conditioning agents

The main performance variables are drug loading, crystallization control, adhesive strength, peel force, wear time, moisture tolerance, and skin reaction rate. FDA-approved lidocaine patches illustrate two different commercial strategies: traditional 5% systems and lower-strength 1.8% systems using a proprietary adhesive and delivery architecture (FDA, 2018, 2018b).

Which excipient strategy is best for lidocaine HCl?

The optimal strategy depends on the target market rather than the active ingredient alone.

Commercial objective	Preferred excipient strategy	Main risk
Low-cost injectable generic	Simple aqueous solution with sodium chloride and pH control	Price competition
Preservative-free hospital product	Single-dose packaging with minimal excipients	Higher packaging and fill-finish cost
Long-wear topical product	Adhesive matrix or high-residence gel	Skin irritation and variable drug release
Sensitive-skin product	Low-irritant preservative system and reduced solvent load	Lower solubility or shorter shelf life
Dental product	Sterile aqueous solution in cartridge with optional epinephrine	Container compatibility and supply-chain complexity
OTC consumer product	Stable cream, gel, spray, or patch with convenient dosing	Labeling and human-factors requirements
Premium specialty product	Device-integrated or combination delivery system	Development cost and patent clearance

A developer should avoid treating excipients as interchangeable. A preservative change can alter antimicrobial effectiveness, local tolerability, extractables, and regulatory classification. A viscosity modifier can affect dose uniformity, syringeability, spray pattern, and bioavailability. A patch adhesive can determine whether the product is commercially usable even when chemical assay results are acceptable.

What FDA regulatory pathway applies to lidocaine HCl products?

Lidocaine HCl products may be regulated as prescription drugs, over-the-counter drugs, or combination products depending on dosage form, strength, route, indication, and delivery system.

Generic injectable and topical products

A conventional generic may use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant generally must demonstrate pharmaceutical equivalence and bioequivalence where applicable. Injectable products may qualify for biowaivers when the formulation and route satisfy FDA requirements, but the applicant still must address sterility, stability, container closure, and inactive-ingredient suitability.

For topical products, the evidentiary burden depends on the dosage form and whether the product is intended to be locally or systemically acting. FDA may require comparative physicochemical characterization, in vitro release testing, pharmacokinetic studies, or clinical endpoint data.

New delivery systems

A new lidocaine patch, spray device, microneedle system, or combination product may require a 505(b)(2) application rather than a conventional ANDA. This pathway can support reliance on published literature or FDA findings for lidocaine while requiring new data for the delivery platform, indication, or formulation.

OTC products

Some lidocaine topical products may be marketed under an applicable OTC monograph or through an approved application. The permitted strength, indication, labeling, and dosage form must match the governing FDA framework. A product with a novel delivery system, unrecognized excipient, or new claim may require an NDA or 505(b)(2) submission.

What patents protect lidocaine HCl products?

Lidocaine HCl has no meaningful remaining composition-of-matter exclusivity in the United States. The active ingredient was introduced decades ago, and conventional lidocaine injections and creams are generally exposed to generic competition.

Patent value can still exist in the following areas:

1. Transdermal systems, including adhesive composition, drug-in-adhesive architecture, backing layers, and release liners.
2. Topical formulations with defined ratios of lidocaine, solvents, polymers, emulsifiers, or permeation enhancers.
3. Combination products containing lidocaine with epinephrine, prilocaine, tetracaine, antiseptics, corticosteroids, or other active ingredients.
4. Metered-dose sprays, applicators, cartridges, and other delivery devices.
5. Sustained-release depots, liposomes, nanoparticles, microspheres, and injectable implants.
6. Manufacturing processes that control crystallization, particle size, drug loading, or sterile processing.
7. Specific methods of use, including dosing regimens, administration sites, and treatment of defined pain conditions.

Formulation patent strength

The strongest patent claims usually require a narrow combination of measurable features, such as:

• A specified lidocaine concentration
• A defined polymer or adhesive composition
• A controlled release profile
• A particular skin flux or residence time
• A defined pH or particle-size range
• A specific device structure
• A clinical or functional result linked to the formulation

Broad claims covering "a pharmaceutical composition comprising lidocaine" are vulnerable to invalidity and design-around challenges because lidocaine formulations are heavily documented in the prior art.

What is the Orange Book status of lidocaine HCl?

Lidocaine HCl has multiple FDA-approved products, but Orange Book relevance depends on the specific reference product and dosage form. Conventional lidocaine injections and many topical products are mature generic categories. Patent listings, if present for a particular branded product, are more likely to concern a delivery system, formulation, or method of use than the active ingredient itself.

Orange Book-listed patents do not automatically block all lidocaine products. The scope depends on the listed claims, the dosage form, the approved labeling, and the proposed generic’s formulation and use.

For an ANDA applicant, the principal patent strategies are:

• Paragraph I certification when no patent information is listed
• Paragraph II certification when listed patents have expired
• Paragraph III certification for approval after patent expiration
• Paragraph IV certification when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed
• Section viii statement when the applicant omits a patented method of use from labeling

The 30-month stay risk applies when the patent holder or NDA owner files an infringement action within the statutory period after receiving a Paragraph IV notice. The practical risk is product-specific and cannot be assessed from the lidocaine molecule alone.

When does lidocaine HCl lose exclusivity?

Lidocaine HCl already has lost basic active-ingredient exclusivity. Commercial exclusivity persists only where it is attached to a specific product, delivery platform, indication, or regulatory designation.

Exclusivity type	Lidocaine HCl status
Composition-of-matter patent	Expired
Conventional injectable generic entry	Broadly available
Conventional topical generic entry	Broadly available, subject to dosage form
Product-specific formulation patent	May remain for selected branded systems
Method-of-use patent	Possible for narrow labeled uses
Orphan-drug exclusivity	Not generally associated with ordinary lidocaine products
Pediatric exclusivity	Product-specific and uncommon in the core market
Biosimilar exclusivity	Not applicable

The absence of molecule-level exclusivity makes formulation and execution the central competitive variables.

Which companies are challenging lidocaine HCl products?

Competition comes from several groups:

• Generic manufacturers supplying injectable and topical products
• Hospital-focused manufacturers of sterile injectables
• Dental pharmaceutical companies supplying cartridges
• Consumer-health companies selling creams, gels, sprays, and patches
• Specialty pharmaceutical companies developing proprietary topical delivery systems
• Contract manufacturers producing private-label lidocaine products

For mature injectable products, competition is often driven by manufacturing capacity, shortage avoidance, contract pricing, and hospital purchasing contracts. For topical and transdermal products, brand differentiation can be stronger because consumers and clinicians evaluate adhesion, onset, duration, mess, odor, and skin tolerability.

What generic launch risks exist for lidocaine HCl?

The probability of generic entry is high for simple aqueous injections and conventional topical products. The main barriers are operational rather than molecular.

Sterile manufacturing risk

Injectable products require validated aseptic processing or terminal sterilization where compatible. Container closure, particulate control, endotoxin limits, and visual inspection can delay launch. Dental cartridges add constraints involving rubber components, glass, aluminum seals, and pressure or breakage performance.

Excipient and formulation risk

A generic cannot assume that every inactive ingredient is acceptable for every route. FDA’s Inactive Ingredient Database can support regulatory precedent, but route-specific exposure and concentration remain relevant (FDA, 2024).

Device and adhesive risk

A patch applicant must demonstrate consistent drug release and acceptable adhesion across temperature, humidity, movement, and skin types. Small changes in tackifier, polymer grade, or solvent level can materially affect performance.

Supply-chain risk

Lidocaine HCl itself is widely available, but disruptions can occur in sterile vials, cartridges, specialty polymers, adhesive films, and approved preservative systems. Dual sourcing is commercially valuable, but switching suppliers can require comparability work and regulatory supplements.

How strong is the patent estate for lidocaine HCl?

The estate is weak for the active ingredient and basic formulations, moderate for specialized dosage forms, and potentially strong for commercially successful delivery platforms.

Asset type	Patent strength	Main reason
Plain lidocaine HCl injection	Low	Mature chemistry and extensive prior art
Preservative-free injection	Low to moderate	Packaging and process claims may add protection
Conventional 2% gel or 5% cream	Low	Crowded formulation field
Long-wear transdermal patch	Moderate to high	Adhesive, matrix, and release claims can be specific
Liposomal or sustained-release lidocaine	Moderate	Technical complexity, but substantial prior art
Lidocaine combination product	Moderate	Strength depends on combination and indication
Novel applicator or metered spray	Moderate	Device and use claims may support differentiation
Manufacturing process	Moderate	Useful if process produces measurable product advantages

Patent owners should pair formulation claims with process, device, and method-of-use claims. A single narrow formulation patent may be easier to design around than a coordinated portfolio.

What licensing deals are relevant to lidocaine HCl?

Lidocaine HCl licensing opportunities usually concern technology rather than the active ingredient. Potential deal structures include:

• Licensing a proprietary patch adhesive or matrix
• Acquiring rights to a sustained-release injectable platform
• Partnering on dental or hospital distribution
• Licensing a preservative-free multidose container system
• Commercializing a consumer-health product under private-label rights
• Obtaining regional rights to an approved 505(b)(2) product

The commercial value of a license depends on regulatory status, manufacturing readiness, freedom to operate, reimbursement, and whether the product has a defensible delivery advantage. A license to unapproved lidocaine formulation technology without clinical or regulatory validation has limited value compared with a product supported by FDA data and scalable manufacturing.

How does lidocaine HCl compare with competing local anesthetics?

Active ingredient	Main advantage	Main limitation	Excipient opportunity
Lidocaine HCl	Familiarity, rapid onset, broad regulatory history	Limited duration in many uses	Long-residence gels, patches, and combinations
Prilocaine HCl	Often used in combination with lidocaine	Methemoglobinemia risk in susceptible patients	Balanced topical systems
Bupivacaine HCl	Longer duration	Greater cardiotoxicity concern	Controlled-release injectable systems
Ropivacaine HCl	Long-acting regional anesthesia profile	Higher cost and clinical-use constraints	Hospital-focused depot products
Tetracaine HCl	Potent topical anesthesia	Narrower safety margin	Ophthalmic and specialty formulations

Lidocaine’s strongest commercial advantage is its established use across many settings. Its weakness is commoditization. Product developers therefore need to improve duration, tolerability, dosing convenience, or site-specific delivery.

What commercial opportunities are most attractive?

The most actionable opportunities are:

1. Preservative-free injectable presentations for hospital, neuraxial, ophthalmic, and procedural use.
2. Low-irritation topical creams and gels for repeated consumer use.
3. Thin, flexible patches with improved adhesion and low residue.
4. Combination patches or gels with complementary analgesic or anti-inflammatory agents.
5. Metered sprays that reduce dosing variability.
6. Dental cartridges with improved stability, ergonomic packaging, or supply reliability.
7. Pediatric and geriatric products with calibrated dosing and safer packaging.
8. Sustained-release local anesthetic systems for postoperative pain.
9. Formulations compatible with home procedures and telehealth-supported care.
10. Regional products that address shortages of sterile lidocaine presentations.

Manufacturers should prioritize products where excipient choice produces a measurable benefit: longer wear, lower irritation, faster onset, improved dose uniformity, or reduced administration frequency.

Key Takeaways

• Lidocaine HCl has no meaningful remaining molecule-level exclusivity.
• Conventional injections and basic topical products face intense generic competition.
• Excipient selection is central to product performance, safety, and regulatory acceptance.
• Preservative-free systems, advanced patches, sustained-release products, and metered devices offer the strongest differentiation.
• Patent protection is more credible for delivery systems, manufacturing processes, devices, and narrow methods of use than for basic lidocaine formulations.
• Biosimilar competition does not apply because lidocaine HCl is a small-molecule drug.
• Commercial success depends on sterile manufacturing, adhesive performance, packaging, supply reliability, and evidence of a practical clinical advantage.

FAQs About Lidocaine HCl Excipient and Patent Strategy

Can propylene glycol be used in every lidocaine HCl topical product?

No. Propylene glycol is widely used as a solvent and penetration enhancer, but concentration, route, age group, damaged-skin exposure, and irritation potential must be evaluated. Its regulatory precedent does not eliminate the need for product-specific safety and stability work.

Is a preservative-free lidocaine injection patentable?

A preservative-free composition alone is usually a weak patent position because preservative-free lidocaine injections are known. Stronger claims may focus on a specific container, closure, stability profile, multidose system, or manufacturing process that produces a non-obvious technical result.

Can a lidocaine patch qualify for an ANDA?

Potentially, but the pathway depends on the reference product and the degree of formulation and device similarity. A materially different patch architecture, adhesive, indication, or release profile may require a 505(b)(2) application or another FDA pathway.

Does lidocaine HCl require a biosimilar development program?

No. Biosimilar regulation applies to biological products. Lidocaine HCl is a chemically synthesized small molecule and is generally developed through generic, NDA, or 505(b)(2) pathways.

What is the main barrier to launching a generic lidocaine injection?

The main barriers are sterile manufacturing, validated container closure, particulate and endotoxin control, reliable supply, and regulatory compliance. The active pharmaceutical ingredient itself is not the primary barrier.

References

1. U.S. Food and Drug Administration. (2018a). Xylocaine (lidocaine hydrochloride) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2018b). ZTlido (lidocaine topical system) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.